🚀 VC round data is live in beta, check it out!
Cochlear Valuation Multiples
Discover revenue and EBITDA valuation multiples for Cochlear and similar public comparables like Bio-Rad Laboratories, Demant, Glaukos, Shimadzu and more.
Cochlear Overview
About Cochlear
Cochlear is the leading cochlear implant device manufacturer with around 60% global market share. Developed markets contribute 80% of group revenue where cochlear implants are the standard of care for children with severe to profound hearing loss. The company also actively targets the growing cohort of seniors in developed markets. Tender-oriented emerging markets contribute the remaining 20% of group revenue. Main products include cochlear implants, bone-anchored hearing aids, and associated sound processors. In fiscal 2025, 49% of revenue came from the Americas, 34% from Europe, the Middle East, and Africa, and 18% from the Asia-Pacific segment.
Founded
1983
HQ
Employees
5.5K
Website
Financials (LTM)
EV
$8B
Cochlear Financials
Cochlear reported last 12-month revenue of $2B and EBITDA of $444M.
In the same LTM period, Cochlear generated $1B in gross profit, $444M in EBITDA, and $292M in net income.
Revenue (LTM)
Cochlear P&L
In the most recent fiscal year, Cochlear reported revenue of $2B and EBITDA of $445M.
Cochlear expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $1B | XXX | XXX | XXX |
| Gross Margin | 74% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $444M | XXX | $445M | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBIT Margin | 22% | XXX | 20% | XXX | XXX | XXX |
| Net Profit | $292M | XXX | $279M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Cochlear Stock Performance
Cochlear has current market cap of $8B, and enterprise value of $8B.
Market Cap Evolution
Cochlear's stock price is $120.60.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8B | $8B | 0.0% | XXX | XXX | XXX | $4.27 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCochlear Valuation Multiples
Cochlear trades at 4.6x EV/Revenue multiple, and 17.9x EV/EBITDA.
EV / Revenue (LTM)
Cochlear Financial Valuation Multiples
As of April 19, 2026, Cochlear has market cap of $8B and EV of $8B.
Equity research analysts estimate Cochlear's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Cochlear has a P/E ratio of 27.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV (current) | $8B | XXX | $8B | XXX | XXX | XXX |
| EV/Revenue | 4.6x | XXX | 4.7x | XXX | XXX | XXX |
| EV/EBITDA | 17.9x | XXX | 17.8x | XXX | XXX | XXX |
| EV/EBIT | 21.1x | XXX | 23.2x | XXX | XXX | XXX |
| EV/Gross Profit | 6.3x | XXX | 6.4x | XXX | XXX | XXX |
| P/E | 27.0x | XXX | 28.3x | XXX | XXX | XXX |
| EV/FCF | 32.4x | XXX | 78.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cochlear Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Cochlear Margins & Growth Rates
Cochlear's revenue in the last 12 month grew by 10%.
Cochlear's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.2M for the same period.
Cochlear's rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Cochlear's rule of X is 43% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Cochlear Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 26% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 31% | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 7% | XXX | 9% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | 12% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Cochlear Public Comps
See public comps and valuation multiples for other Medical Devices comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Cochlear | XXX | XXX | XXX | XXX | XXX | XXX |
| Bio-Rad Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Demant | XXX | XXX | XXX | XXX | XXX | XXX |
| Glaukos | XXX | XXX | XXX | XXX | XXX | XXX |
| Shimadzu | XXX | XXX | XXX | XXX | XXX | XXX |
| Masimo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cochlear M&A Activity
Cochlear acquired XXX companies to date.
Last acquisition by Cochlear was on XXXXXXXX, XXXXX. Cochlear acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Cochlear
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialCochlear Investment Activity
Cochlear invested in XXX companies to date.
Cochlear made its latest investment on XXXXXXXX, XXXXX. Cochlear invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Cochlear
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cochlear
| When was Cochlear founded? | Cochlear was founded in 1983. |
| Where is Cochlear headquartered? | Cochlear is headquartered in Australia. |
| How many employees does Cochlear have? | As of today, Cochlear has over 5K employees. |
| Who is the CEO of Cochlear? | Cochlear's CEO is Dig Howitt. |
| Is Cochlear publicly listed? | Yes, Cochlear is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Cochlear? | Cochlear trades under COH ticker. |
| When did Cochlear go public? | Cochlear went public in 1995. |
| Who are competitors of Cochlear? | Cochlear main competitors are Bio-Rad Laboratories, Demant, Glaukos, Shimadzu. |
| What is the current market cap of Cochlear? | Cochlear's current market cap is $8B. |
| What is the current revenue of Cochlear? | Cochlear's last 12 months revenue is $2B. |
| What is the current revenue growth of Cochlear? | Cochlear revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Cochlear? | Current revenue multiple of Cochlear is 4.6x. |
| Is Cochlear profitable? | Yes, Cochlear is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Cochlear? | Cochlear's last 12 months EBITDA is $444M. |
| What is Cochlear's EBITDA margin? | Cochlear's last 12 months EBITDA margin is 26%. |
| What is the current EV/EBITDA multiple of Cochlear? | Current EBITDA multiple of Cochlear is 17.9x. |
| What is the current FCF of Cochlear? | Cochlear's last 12 months FCF is $244M. |
| What is Cochlear's FCF margin? | Cochlear's last 12 months FCF margin is 14%. |
| What is the current EV/FCF multiple of Cochlear? | Current FCF multiple of Cochlear is 32.4x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.